A carregar...
P14.15 Benefit of Bevacizumab for recurrent glioblastoma. Results of 81 patients from a single institution
BACKGROUND: No standard of care has been established for patients with progressive glioblastoma (rGBM). Previous studies suggested that bevacizumab (BEV) is safe and produces responses that result in a decreased use of glucocorticoids and increased progression-free survival (PFS) with an unclear eff...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6795927/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.250 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|